Cellectis SA (CLLS)
1.43
+0.03
(+2.14%)
USD |
NASDAQ |
Oct 02, 16:00
1.41
-0.02
(-1.40%)
After-Hours: 20:00
Cellectis EPS Diluted (Quarterly) : -0.2165 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2165 |
| March 31, 2026 | -0.1774 |
| December 31, 2025 | -0.2621 |
| September 30, 2025 | 0.0058 |
| June 30, 2025 | -0.2398 |
| March 31, 2025 | -0.181 |
| December 31, 2024 | 0.0816 |
| September 30, 2024 | -0.2303 |
| June 30, 2024 | -0.28 |
| March 31, 2024 | 0.0547 |
| December 31, 2023 | -0.5974 |
| September 30, 2023 | -0.3145 |
| June 30, 2023 | -11.69M |
| March 31, 2023 | -0.5845 |
| December 31, 2022 | -0.5874 |
| September 30, 2022 | -0.6212 |
| June 30, 2022 | -0.413 |
| March 31, 2022 | -0.7425 |
| December 31, 2021 | -0.5495 |
| September 30, 2021 | -0.8228 |
| June 30, 2021 | -0.8781 |
| March 31, 2021 | -0.2769 |
| December 31, 2020 | -0.9267 |
| Date | Value |
|---|---|
| September 30, 2020 | -0.7138 |
| June 30, 2020 | -0.7596 |
| March 31, 2020 | 0.4725 |
| December 31, 2019 | -0.8765 |
| September 30, 2019 | -0.3769 |
| June 30, 2019 | -0.7881 |
| March 31, 2019 | -0.3594 |
| December 31, 2018 | -0.5438 |
| September 30, 2018 | -0.5377 |
| June 30, 2018 | -0.17 |
| March 31, 2018 | -0.71 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | -0.7759 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | -0.3772 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | -0.2032 |
| March 31, 2016 | -0.9151 |
| December 31, 2015 | 0.2517 |
| September 30, 2015 | -0.4001 |
| June 30, 2015 | -0.6969 |
| March 31, 2015 | 0.2136 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| DBV Technologies SA | -0.5804 |
| Akari Therapeutics Plc | -2.404 |
| Autolus Therapeutics Plc | -0.1472 |
| Evaxion AS | -0.4464 |
| Bicycle Therapeutics Plc | -0.7224 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -21.79M |
| Revenue (Quarterly) | 5.222M |
| Total Expenses (Quarterly) | 27.01M |
| Enterprise Value | 81.43M |
| Gross Profit Margin (Quarterly) | 15.62% |
| Profit Margin (Quarterly) | -417.3% |
| Earnings Yield | -45.47% |
| Normalized Earnings Yield | -41.86 |